| Name | Title | Contact Details |
|---|
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.
Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.
Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families. Roivant`s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system. Roivant is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. We deliver R&D solutions to our partners in the biopharmaceutical industry, helping them unlock value from their pipelines by completing the clinical development of promising drug candidates. Our pipeline spans multiple therapeutic areas through partnerships with academic institutions and pharmaceutical companies, including Takeda, Merck, GlaxoSmithKline, Vertex, Eisai, Arena Pharmaceuticals, Portola Pharmaceutcals, Duke University, and Cincinnati Children`s Hospital Medical Center.
At the forefront of the medical and digital revolutions, Voluntis is a pioneer of digital therapeutics. We design prescription applications that embed medical intelligence in the smartphones of people suffering from chronic and rare diseases. By using our software, patients leverage their health data to simplify their medical care. Treatment is personalized, doctors and patients are connected to coordinate care and real-world outcomes are improved. Harnessing its proprietary technology, Voluntis has developed digital solutions for diabetes, respiratory diseases, cancer, anticoagulation and hemophilia. Whether in our French or US offices, we are always on the look out for talent that is passionate about digital technologies and changing patients` lives.
Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.